NCT07114666尚未招募不适用
Efficacy and Safety of XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- OS
研究概览
简要总结
This is a single-center, open label, single-arm, investigator-initiated study to evaluate the efficacy and safety of XH001 (neoantigen cancer vaccine) in combination with chemotherapy as Adjuvant Therapy in pancreatic cancer patients following surgical resection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of signed and dated informed consent form;
- •Aged 18 to 75 years old;
- •Histologically or cytologically confirmed pancreatic ductal adenocarcinoma;
- •R0 or R1 surgical resection as determined by pathology；
- •Have not received any prior neoadjuvant therapy;
- •ECOG score is 0 or 1;
- •Patients must have adequate organ and marrow function defined by study-specified laboratory tests prior to initial study drug.
- •Woman of childbearing potential must have a negative pregnancy test and follow contraceptive guidelines as defined per protocol.
排除标准
- •Borderline resectable pancreatic cancer;
- •Evidence of metastasis or disease recurrence following surgical resection at any time;
- •Evidence of malignant ascites;
- •Pre-existing inflammatory bowel disease or the presence of complete or partial bowel obstruction, or persistent severe diarrhea after surgery;
- •Needs to receive long-term systemic anti-allergic drug or known hypersensitivity to any component of the study treatment;
- •History of autoimmune disease;
- •Cerebrovascular accident (including ischemic stroke, hemorrhagic stroke, and transient ischemic attack) within 6 months before screening;
- •Acute myocardial infarction within 6 months before screening, or uncontrolled angina, uncontrolled arrhythmia, severe heart failure (see Appendix 3, New York Heart Association Heart Failure Classification Criteria NYHA Class ≥ III) and other cardiovascular diseases;
- •Received immunomodulatory medications within 4 weeks prior to the date of the first dose (D1) of XH001, including but not limited to: IL-2, CTLA-4 inhibitors, CD40 agonists, CD137 agonists, IFN-α;
- •Received blood transfusion, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) within 7 days prior to the first dose of XH001;
- •Received therapeutic tumor vaccines;
- •With congenital or acquired immunodeficiency;
- •Participating in other clinical trials and not enrolled at the screening period;
- •Unable or unwilling to comply with the study protocol due to potential health, mental or social conditions in the opinion of the investigator;
- •Other conditions that, in the opinion of the investigator, would make participation in this study inappropriate.
研究组 & 干预措施
XH001 (dose 1)
Experimental
Biological: XH001
- mRNA neoantigen cancer vaccine（Dose 1） Drug: Chemotherapy
- gemcitabine+capecitabine
- oxaliplatin+lrinotecan+calcium folinate+5-FU
干预措施: XH001 (Biological)
XH001 (dose 1)
Experimental
Biological: XH001
- mRNA neoantigen cancer vaccine（Dose 1） Drug: Chemotherapy
- gemcitabine+capecitabine
- oxaliplatin+lrinotecan+calcium folinate+5-FU
干预措施: Chemotherapy (Drug)
XH001 (dose 2)
Experimental
Biological: XH001
- mRNA neoantigen cancer vaccine(Dose 2) Drug: Chemotherapy
- gemcitabine+capecitabine
- oxaliplatin+lrinotecan+calcium folinate+5-FU
干预措施: XH001 (Biological)
XH001 (dose 2)
Experimental
Biological: XH001
- mRNA neoantigen cancer vaccine(Dose 2) Drug: Chemotherapy
- gemcitabine+capecitabine
- oxaliplatin+lrinotecan+calcium folinate+5-FU
干预措施: Chemotherapy (Drug)
结局指标
主要结局
OS
时间窗: up to 48 months
Overall survival
DFS
时间窗: From operation up to 36 months
Disease Free Survival
DFS Rate
时间窗: 12,24 and 36 months
Disease-free survival rate
MFS
时间窗: up to 36 months
metastasis-free survival
次要结局
- Adverse Event(up to 36 months)
- Specific immune response(up to 36 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic CancerPancreatic CancerNCT06353646Wu Wenming28
招募中
不适用
A Safety and Efficacy Study of XH001 Combined With Sintilimab Injection in Advanced Solid TumorsSolid TumorNCT05940181jianming xu9
Unknown
2 期
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder CancerBladder CancerNCT04738630Taizhou Hanzhong biomedical co. LTD110
已完成
2 期
An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida AurisCandidemiaInvasive CandidiasesCandida InfectionNCT04148287Basilea Pharmaceutica9
已完成
1 期
Evaluate the Safety and Efficacy of HLX04-O in Subjects With wAMDAge Related Macular DegenerationNCT04993352Shanghai Henlius Biotech20